COMMUNIQUÉS West-GlobeNewswire

Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
03/06/2026
Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete Company reiterates expected Q3 2026 readout for rheumatoid arthritis (RA) and Q4 2026 [...]
Konica Minolta Healthcare Expands Service Offerings and Updates AeroRemote Insights with In-Depth Analytics and Operational Intelligence to Help Facilities Address Current Department Challenges
03/06/2026
WAYNE, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Imaging departments are increasingly being tasked to improve efficiency and workflow performance while simultaneously addressing market pressures such as staff shortages [...]
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
03/06/2026
Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36 Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune reset Miv-cel continues to [...]
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
03/06/2026
Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic Outcomes Late-Breaking Preclinical [...]
Denovo to Participate in Upcoming Investor Conferences Highlighting its Biomarker Guided Phase 3 Antidepressant
03/06/2026
SAN DIEGO, June 03, 2026 (GLOBE NEWSWIRE) -- Denovo Neuroscience, a pioneer in applying precision medicine in central nervous system (CNS) diseases, today announced that members of the Company’s management team will [...]
Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome
03/06/2026
New Drug Application (NDA) enabling Phase 2b Protocol submission to the U.S. FDA Targets Rare Disease Population with Significant Unmet Need and Lifetime Burden of Repeated Skin Cancer Surgeries PHILADELPHIA, June 03, [...]
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
03/06/2026
Appointment supports Celularity’s focus on longevity, regenerative medicine and preservation of human performance by advancing commercialization of cenplacel-L and Lifebank FLORHAM PARK, N.J., June 03, 2026 (GLOBE [...]
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
03/06/2026
CONSHOHOCKEN, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 47 th Annual Global Goldman Sachs Health Care Conference 2026 [...]
Noah Medical Appoints Dr. Krish Bhadra as Chief Pulmonary Advisor
03/06/2026
Pioneering Physician and Interventional Pulmonology Innovator Joins Noah Medical to Accelerate the Next Era of Robotic-Assisted Lung Cancer Diagnosis and Treatment SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- [...]
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
03/06/2026
CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
03/06/2026
Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populations This is the second published manuscript from the Genital Psoriasis [...]
Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
03/06/2026
– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer [...]
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
03/06/2026
Phase 1b INFLO-1 study data readout anticipated in Q3 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical company focused on [...]
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
03/06/2026
RADNOR, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic [...]
Making Democracy Cute Again: Cutest Pets on Parliament Hill Crowns 2026 Winners
03/06/2026
OTTAWA, Ontario, June 03, 2026 (GLOBE NEWSWIRE) -- After weeks of spirited campaigning, fierce competition and over 19,000 votes from Canadians across the country, the winners of the 2026 Cutest Pets on Parliament Hill [...]
Rendre la démocratie attirante de nouveau : le concours « Les animaux de compagnie les plus mignons sur la Colline du Parlement » dévoile ses lauréats 2026
03/06/2026
OTTAWA, Ontario, 03 juin 2026 (GLOBE NEWSWIRE) -- Après des semaines de campagne acharnée, de compétition féroce et plus de 19 000 votes de Canadiens à l’échelle du pays, les lauréats du concours « Les animaux de [...]
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
03/06/2026
– Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met – – $500 million committed under senior secured term [...]
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
03/06/2026
Expands availability of Nociscan in the greater Los Angeles area with leading neuroscience group Adds to growing body of real-world evidence with study comparing chemical biomarker data from Nociscan with bone metabolic [...]
Hopstem hNPC01 Cell Injection Earns FDA RMAT Designation for Chronic Stroke Therapy
03/06/2026
HOUSTON, June 03, 2026 (GLOBE NEWSWIRE) -- Hopstem Biotechnology, a clinical-stage biotech specializing in iPSC-derived cell therapeutics for neurological diseases, has secured the first Regenerative Medicine Advanced [...]

Pages